IRIS
DUMINUCO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.752
EU - Europa 1.530
AS - Asia 1.514
AF - Africa 246
SA - Sud America 174
OC - Oceania 5
Totale 5.221
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.696
SG - Singapore 683
RU - Federazione Russa 627
IT - Italia 592
CN - Cina 461
CI - Costa d'Avorio 147
BR - Brasile 143
KR - Corea 133
VN - Vietnam 98
IE - Irlanda 54
FR - Francia 52
GB - Regno Unito 37
FI - Finlandia 35
IN - India 35
CA - Canada 29
NG - Nigeria 27
BJ - Benin 21
HK - Hong Kong 21
SN - Senegal 21
DE - Germania 20
BD - Bangladesh 18
MX - Messico 18
PL - Polonia 17
NL - Olanda 16
SE - Svezia 16
AR - Argentina 14
UA - Ucraina 14
IQ - Iraq 13
ZA - Sudafrica 13
ES - Italia 10
JP - Giappone 10
TR - Turchia 10
BE - Belgio 9
CZ - Repubblica Ceca 7
VE - Venezuela 6
AU - Australia 5
EG - Egitto 5
PK - Pakistan 5
GT - Guatemala 4
JO - Giordania 4
KE - Kenya 4
LT - Lituania 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BO - Bolivia 3
CO - Colombia 3
DZ - Algeria 3
HR - Croazia 3
LB - Libano 3
RO - Romania 3
AZ - Azerbaigian 2
CY - Cipro 2
EC - Ecuador 2
KZ - Kazakistan 2
OM - Oman 2
PH - Filippine 2
PT - Portogallo 2
PY - Paraguay 2
SI - Slovenia 2
BF - Burkina Faso 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
CL - Cile 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HN - Honduras 1
HU - Ungheria 1
ID - Indonesia 1
JM - Giamaica 1
KW - Kuwait 1
LV - Lettonia 1
MA - Marocco 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SO - Somalia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 5.221
Salva come PNG Salva come JPEG
Città #
Singapore 477
Dallas 347
Moscow 330
Santa Clara 242
Hefei 237
San Jose 162
Ashburn 158
Abidjan 147
Seoul 133
Chicago 117
Catania 97
Los Angeles 84
Beijing 53
Dublin 52
Civitanova Marche 48
Palermo 46
Chandler 43
Rome 40
Boardman 38
Lauterbourg 38
Milan 38
Council Bluffs 36
Ho Chi Minh City 34
Buffalo 30
New York 27
Cotonou 21
Dakar 21
São Paulo 19
Hanoi 18
Hong Kong 18
Lagos 18
Lappeenranta 18
Orem 18
Warsaw 17
Montreal 16
Bari 13
Chennai 13
Florence 12
Helsinki 12
Johannesburg 12
Stockholm 12
Amsterdam 11
Boston 11
Naples 10
Tokyo 10
Abuja 9
Brussels 9
Denver 9
Misterbianco 9
Paris 9
Bronte 8
London 8
Messina 8
Munich 8
Phoenix 8
Rio de Janeiro 8
Turin 8
Atlanta 7
Manchester 7
Poplar 7
Seattle 7
Washington 7
Belo Horizonte 6
Cambridge 6
Frankfurt am Main 6
Lawrence 6
Mexico City 6
Mumbai 6
San Francisco 6
Cassano delle Murge 5
City of London 5
Houston 5
Piazzola Sul Brenta 5
San Giovanni la Punta 5
Turku 5
Acireale 4
Ankara 4
Baghdad 4
Brno 4
Brooklyn 4
Genoa 4
Haiphong 4
Kyiv 4
Melbourne 4
Pittsburgh 4
Aci Sant'Antonio 3
Amman 3
Bắc Ninh 3
Cairo 3
Caltagirone 3
Campinas 3
Can Tho 3
Curitiba 3
Lamezia Terme 3
Manassas 3
Marseille 3
Militello in Val di Catania 3
Nairobi 3
New Delhi 3
Olomouc 3
Totale 3.647
Salva come PNG Salva come JPEG
Nome #
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 181
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 180
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 167
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 162
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 159
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 156
A case of high-risk AML in a patient with advanced systemic mastocytosis 154
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 149
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 147
Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report 136
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 135
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 132
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 132
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 126
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study 126
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 125
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 124
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 123
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients 122
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 122
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 119
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 117
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 116
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study 115
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 113
Emergencies in Hematology: Why, When and How I Treat? 112
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 112
Emerging Therapeutic Approaches for Anemia in Myelofibrosis 111
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 110
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases 108
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes 105
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease 103
Chemotherapy extravasation: diagnosis, prevention and management 99
VEXAS-like syndrome: a potential new entity? 99
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association 96
Multicentric Castleman disease and concurrent hematological disorders: the occurrence of plasmacytoma and the hypotheses arising from literature's review 95
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 90
Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma 86
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms 77
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey 76
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? 72
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors 68
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib 67
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study 65
Myelofibrosis: In Search for BETter Targeted Therapies 58
Exploring the ABO haplotype and splanchnic thrombosis in patients with Primary Myelofibrosis 24
Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib 1
Pericytes and mesenchymal stromal cells converge toward pro-tumor phenotypes in the tumor microenvironment 1
Totale 5.273
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.401
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.401
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202252 0 0 0 0 6 4 3 1 6 14 5 13
2022/2023230 7 15 5 12 12 20 7 43 51 14 34 10
2023/2024474 26 60 22 55 13 88 33 36 6 17 80 38
2024/20251.189 16 174 41 114 190 121 60 45 71 85 123 149
2025/20263.328 226 425 411 224 425 765 263 83 233 228 45 0
Totale 5.273